Literature DB >> 15337038

Effect of histologic type and smoking status on interpretation of serum carcinoembryonic antigen value in non-small cell lung carcinoma.

Morihito Okada1, Wataru Nishio, Toshihiko Sakamoto, Kazuya Uchino, Tsuyoshi Yuki, Akio Nakagawa, Noriaki Tsubota.   

Abstract

BACKGROUND: Serum carcinoembryonic antigen (CEA) has all of the properties desired for a biologic measure to be used as a prognostic indicator in the clinical evaluation of lung cancer. Carcinoembryonic antigen value appears to be related to tumor histologic type and patients' smoking status, which has yet to be intensively analyzed as reports available thus far have consisted of a limited number of patients. This study was undertaken to determine whether the prognostic value of CEA differs according to histologic type in a large group of patients with clinical early-stage lung cancer, and how smoking influences its value.
METHODS: Two series of 694 and 260 consecutive patients who underwent resection for clinical stage I lung adenocarcinoma and squamous cell carcinoma, respectively, were evaluated. We measured serum CEA before and after surgery, and analyzed its prognostic significance in relation to histologic type and its correlation with smoking status.
RESULTS: We found significantly higher CEA levels in patients with adenocarcinomas than in those with squamous cell carcinomas (7.8 versus 5.5 ng/mL; p = 0.0018), but a higher percentage of CEA-positive patients among those with squamous cell carcinoma (109 of 260, 41.9%) than those with adenocarcinoma (245 of 694, 35.3%). Clinical stage I patients with a high preoperative CEA level had a poor prognosis, and for pathologically confirmed stage I patients with a high postoperative CEA level the prognosis was worse. The prognostic value of serum CEA level was thus significantly greater for adenocarcinoma than for squamous cell carcinoma. This was probably because of a much higher proportion of smokers among patients with squamous cell carcinoma. In adenocarcinoma, the growth of which was generally less influenced by smoking, the proportion of CEA-positive smokers (49.3%, 170 of 345) was greater than that of CEA-positive nonsmokers (21.5%, 75 of 349, p < 0.0001). Additionally, in patients with adenocarcinoma, survival of nonsmokers was more greatly influenced by CEA level than that of smokers.
CONCLUSIONS: Although serum CEA values measured before and after surgery are important in identifying patients at high risk of poor survival, its specificity is higher for adenocarcinoma than for squamous cell carcinoma. When serum CEA levels are checked, smoking status of patients, particularly of those with squamous cell carcinoma, should be taken into account.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15337038     DOI: 10.1016/j.athoracsur.2004.03.019

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Young Joo Lee; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Exp Ther Med       Date:  2011-05-12       Impact factor: 2.447

Review 2.  History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer.

Authors:  Haruhiko Nakamura; Toshihide Nishimura
Journal:  Surg Today       Date:  2017-02-22       Impact factor: 2.549

Review 3.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

4.  Important contributions to cardiothoracic surgery by Japanese thoracic and cardiac surgeons.

Authors:  Arthur E Baue
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  2005-04

5.  CEA levels in serum and BAL in patients suffering from lung cancer: correlation with individuals presenting benign lung lesions and healthy volunteers.

Authors:  Konstantinos Charalabopoulos; Agathi Karakosta; George Bablekos; Christos Golias; Alexandros Charalabopoulos; Eleni Tsanou; Dimitrios Peschos; Leonidas Zoganas; Anna Batistatou
Journal:  Med Oncol       Date:  2007       Impact factor: 3.064

6.  The relevance of serum carcinoembryonic antigen as an indicator of brain metastasis detection in advanced non-small cell lung cancer.

Authors:  Dong-Soo Lee; Yeon-Sil Kim; So-Lyoung Jung; Kyo-Young Lee; Jin-Hyoung Kang; Sarah Park; Young-Kyoon Kim; Ie-Ryung Yoo; Byung-Ock Choi; Hong-Seok Jang; Sei-Chul Yoon
Journal:  Tumour Biol       Date:  2012-02-21

7.  Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations.

Authors:  Yuan Gao; PingPing Song; Hui Li; Hui Jia; BaiJiang Zhang
Journal:  BMC Cancer       Date:  2017-07-14       Impact factor: 4.430

8.  Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.

Authors:  Minkyu Jung; Se Hyun Kim; Soojung Hong; Young Ae Kang; Se Kyu Kim; Joon Chang; Sun Young Rha; Joo Hang Kim; Dae Joon Kim; Byoung Chul Cho
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

9.  Brain metastasis development and poor survival associated with carcinoembryonic antigen (CEA) level in advanced non-small cell lung cancer: a prospective analysis.

Authors:  Oscar Arrieta; David Saavedra-Perez; Roberto Kuri; Alejandro Aviles-Salas; Luis Martinez; Daniel Mendoza-Posada; Patricia Castillo; Alma Astorga; Enrique Guzman; Jaime De la Garza
Journal:  BMC Cancer       Date:  2009-04-22       Impact factor: 4.430

10.  Heterogeneous prognosis and adjuvant chemotherapy in pathological stage I non-small cell lung cancer patients.

Authors:  Chia-Hsin Liu; Yi-Jen Peng; Hong-Hau Wang; Ying-Chieh Chen; Chen-Liang Tsai; Chih-Feng Chian; Tsai-Wang Huang
Journal:  Thorac Cancer       Date:  2015-02-27       Impact factor: 3.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.